溶瘤病毒在生物传感器中的研究进展

doi:10.19586/j.2095-2341.2025.0029

生物技术进展 ›› 2025, Vol. 15 ›› Issue (5): 798-803.DOI: 10.19586/j.2095-2341.2025.0029

溶瘤病毒在生物传感器中的研究进展

杨倩(), 宋志灵()

青岛科技大学化学与分子工程学院，山东青岛 266042

收稿日期:2025-03-02 接受日期:2025-03-28 出版日期:2025-09-25 发布日期:2025-11-11
通讯作者: 宋志灵
作者简介:杨倩 E-mail：1049797611@qq.com；
基金资助:
山东省自然科学基金项目(322024054)

Research Advances on Oncolytic Viruses for Biosensors

Qian YANG(), Zhiling SONG()

College of Chemistry and Molecular Engineering，Qingdao University of Science and Technology，Shandong Qingdao 266042，China

Received:2025-03-02 Accepted:2025-03-28 Online:2025-09-25 Published:2025-11-11
Contact: Zhiling SONG

摘要/Abstract

摘要：

溶瘤病毒（oncolytic viruses, OVs）作为一种新兴的肿瘤免疫治疗工具，通过选择性裂解肿瘤细胞和激活抗肿瘤免疫的双重机制，已在多种实体瘤治疗中展现出潜力。近年来，溶瘤病毒与生物传感器的结合为癌症诊疗提供了新思路：通过基因工程改造，溶瘤病毒可作为生物传感器的动态响应元件，实时监测肿瘤微环境（tumor microenvironment, TME）的分子特征，或作为递送载体将生物传感器靶向肿瘤区域，实现治疗与监测的协同。系统综述了溶瘤病毒的作用机制和主要应用领域，以及作为生物传感器的技术基础和相关的临床研究进展，并展望了未来的发展方向。

关键词: 溶瘤病毒, 肿瘤, 生物传感器

Abstract:

Oncolytic viruses （OVs）， as an emerging therapeutic tool in tumor immunotherapy， have demonstrated promising potential in treating various solid tumors by selectively lysing tumor cells and activating anti-tumor immunity. In recent years， the integration of oncolytic viruses with biosensors has introduced a novel approach for cancer diagnosis and treatment： through genetic engineering， OVs can serve as dynamic response elements in biosensors to monitor molecular features of the tumor microenvironment （TME） in real time， or act as delivery vectors to target biosensors to tumor sites， thereby achieving synergistic treatment and monitoring. This paper systematically reviewed the mechanisms of oncolytic viruses and their primary applications， the technical foundations of biosensors， and recent clinical advances， while also prospected future directions.

Key words: oncolytic viruses, tumors, biosensors

中图分类号:

杨倩, 宋志灵. 溶瘤病毒在生物传感器中的研究进展[J]. 生物技术进展, 2025, 15(5): 798-803.

Qian YANG, Zhiling SONG. Research Advances on Oncolytic Viruses for Biosensors[J]. Current Biotechnology, 2025, 15(5): 798-803.

图/表 3

图1 溶瘤病毒及其作用机制[2]

Fig. 1 OVs and their mechanism of action[2]

图2 溶瘤病毒刺激肿瘤细胞免疫示意图[5]

Fig. 2 Schematic representation of the oncolytic virus-stimulated tumor cell immunity[5]

图3 肿瘤细胞病毒感染的宿主要求

Fig. 3 Host requirements for tumor cell virus infection

参考文献 17

[1]	LE BON A, ETCHART N, ROSSMANN C, et al.. Cross-priming of CD8⁺ T cells stimulated by virus-induced type I interferon[J]. Nat. Immunol., 2003, 4(10): 1009-1015.
[2]	TIAN Y, XIE D, YANG L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy[J/OL]. Signal Transduct Target Ther., 2022;7(1):117[2025-08-02]..
[3]	LIU B L, ROBINSON M, HAN Z Q, et al.. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties[J]. Gene Ther., 2003, 10(4): 292-303.
[4]	HAN Z Q, ASSENBERG M, LIU B L, et al.. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy[J]. J. Gene Med., 2007, 9(2): 99-106.
[5]	LAWLER S E, SPERANZA M C, CHO C F, et al.. Oncolytic viruses in cancer treatment: a review[J]. JAMA Oncol., 2017,3(6), 841-849.
[6]	KAUFMAN H L, BINES S D. OPTIM trial: a phase Ⅲ trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage Ⅲ or Ⅳ melanoma[J]. Future Oncol., 2010,6(6), 941-949.
[7]	ANDTBACKA R H, KAUFMAN H L, COLLICHIO F, et al.. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. J. Clin. Oncol., 2015, 33(25): 2780-2788.
[8]	KAUFMAN H L, KOHLHAPP F J, ZLOZA A. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nature Rev. Drug Discov., 2015,14(9), 642-662.
[9]	HAN C, HAO L, CHEN M, et al.. Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3⁺ T cell[J]. Tumour Biol., 2013, 34(5): 2863-2869.
[10]	MA S, QU W, MAO L, et al.. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer[J]. Oncol. Rep., 2012, 27(5): 1443-1450.
[11]	LI Y, ZHANG B, ZHANG H, et al.. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth[J]. J. Cancer Res. Clin. Oncol., 2013, 139(6): 933-941.
[12]	HIRVINEN M, CAPASSO C, GUSE K, et al.. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity[J/OL]. Mol. Ther. Oncolytics, 2016, 3: 16002[2025-03-10]. .
[13]	KEMP V, VAN DEN WOLLENBERG D J M, CAMPS M G M, et al.. Arming oncolytic reovirus with GM-CSF gene to enhance immunity[J]. Cancer Gene Ther., 2019, 26(9-10): 268-281.
[14]	CHARD L S, MANIATI E, WANG P, et al.. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer[J]. Clin. Cancer Res., 2015, 21(2): 405-416.
[15]	ANDTBACKA R H I, KAUFMAN H L, COLLICHIO F, et al.. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. J. Clin. Oncol., 2015, 33(25): 2780-2788.
[16]	KAUFMAN H L, KIM D W, DERAFFELE G, et al.. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma[J]. Ann. Surg. Oncol., 2010, 17(3): 718-730.
[17]	PARK S H, BREITBACH C J, LEE J, et al.. Phase 1b trial of biweekly intravenous pexa-vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer[J]. Mol. Ther., 2015, 23(9): 1532-1540.

溶瘤病毒在生物传感器中的研究进展

Research Advances on Oncolytic Viruses for Biosensors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵璐璐, 洪甜, 郝一然, 陈尔凝, 李静雯, 杜美红. 免疫磁分离技术在循环肿瘤细胞检测中的研究进展[J]. 生物技术进展, 2025, 15(4): 606-614.
[2]	朱丽娜, 宋志灵. 自噬与细胞凋亡：相互作用及其在疾病中的作用[J]. 生物技术进展, 2025, 15(4): 622-626.
[3]	翟晓艺, 张海月, 郭文佳, 董晓刚. 癌相关成纤维细胞在乳腺癌中的研究进展[J]. 生物技术进展, 2025, 15(4): 636-644.
[4]	刘晓雅, 张硕珉, 郑鹏, 马睿, 张朝军. DBNDD1基因在结直肠癌进展过程中的作用与机制研究[J]. 生物技术进展, 2025, 15(4): 726-734.
[5]	乌格叶木日, 武建强. 结晶紫的抗肿瘤作用[J]. 生物技术进展, 2025, 15(2): 226-233.
[6]	孙恺婧, 刘馨泽, 金鑫, 杨雪, 王琦, 李玉, 陈长宝, 万茜淋. 暴马桑黄的抗肿瘤活性成分及其作用机制研究进展[J]. 生物技术进展, 2024, 14(6): 929-936.
[7]	李蓓蓓, 武建强. 肿瘤细胞中FAS介导的非凋亡信号通路研究进展[J]. 生物技术进展, 2024, 14(3): 406-412.
[8]	曾艳, 祝恒成, 杨康. 脱氧核糖核酸酶1在肾细胞癌中的作用及机制研究[J]. 生物技术进展, 2024, 14(3): 486-491.
[9]	梁一鹏, 王迪, 宋昊泽, 石莉红, 佟静媛. 生物信息学分析鉴定骨髓增殖性肿瘤发生发展的免疫调控因子[J]. 生物技术进展, 2024, 14(3): 492-500.
[10]	布尔兰·叶尔肯别克, 郭文佳, 董晓刚. 骨膜蛋白在肿瘤微环境中的作用研究进展[J]. 生物技术进展, 2024, 14(2): 205-210.
[11]	赵维坚, 徐弘庭, 肖向茜, 盛望. 肿瘤干细胞中的Hippo信号通路研究进展[J]. 生物技术进展, 2024, 14(2): 211-220.
[12]	孙莉莉, 安外尔·约麦尔阿卜拉, 刘富中, 布尔兰·叶尔肯别克, 迪丽娜尔·叶尔夏提, 郭文佳. 基于肿瘤相关成纤维细胞基因构建乳腺癌预后预测模型及免疫浸润分析[J]. 生物技术进展, 2024, 14(2): 312-322.
[13]	杨玉琦, 何秀霞. 滚环扩增技术在电化学生物传感器中的应用[J]. 生物技术进展, 2023, 13(6): 863-867.
[14]	张鹏晓, 胡念. 黑色素瘤免疫治疗作用机制研究进展[J]. 生物技术进展, 2023, 13(6): 900-906.
[15]	安外尔·约麦尔阿卜拉, 孙莉莉, 布尔兰·叶尔肯别克, 郭文佳. Piezo1在癌症中的作用研究进展[J]. 生物技术进展, 2023, 13(5): 712-717.